文献速递造血干细胞移植与细胞治疗淋巴瘤

利妥昔单抗联合方案一线治疗异基因造血干细胞移植后慢性移植物抗宿主病:2期研究结果

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
PubMed 文献 · Blood · 2017-09-01

这项2期前瞻性多中心试验评估在糖皮质激素和环孢素A基础上加用利妥昔单抗一线治疗异基因造血干细胞移植后新诊断慢性移植物抗宿主病。纳入24例患者,1年时20/24例(83%)有反应,19例可评估患者中14例(74%)停用糖皮质激素,估计1年总生存率83%,1年非复发死亡率累积发生率为14%。

要点

  • 24例轻至重度cGVHD患者接受利妥昔单抗375 mg/m2每周1次共4周,部分缓解者1个月后接受第二疗程。
  • 1年时20/24例(83%)有反应,19例可评估患者中14例(74%)停用糖皮质激素。
  • 估计1年总生存率83%,1年非复发死亡率累积发生率为14%,1例死于进行性多灶性白质脑病。

核心结论

  • 在糖皮质激素和环孢素A基础上加用利妥昔单抗一线治疗cGVHD似乎安全有效。
  • 数据提示该疗效可能部分与对PD-L1hi B细胞和Tfh细胞的作用有关。

研究设计与样本

  • 2期、前瞻性、多中心试验,测试在糖皮质激素和环孢素A基础上加用利妥昔单抗一线治疗异基因造血干细胞移植后新诊断cGVHD的疗效。
  • 纳入24例患者,中位年龄47岁,cGVHD轻度2例、中度7例、重度15例。
  • 所有患者接受利妥昔单抗375 mg/m2每周1次共4周,部分缓解者在1个月后接受第二疗程。
  • 研究注册于www.clinicaltrials.gov,标识号NCT01135641。

主要发现

  • 1年时24例中20例(83%)有反应。
  • 19例可评估患者中14例(74%)停用糖皮质激素。
  • 估计1年总生存率为83%,1年非复发死亡率累积发生率为14%。
  • 1例患者死于进行性多灶性白质脑病。
  • cGVHD诊断时PD-L1hi初始B细胞显著减少,抗CD20 B细胞清除后增加;利妥昔单抗治疗后活化ICOS Hi PD-1hi循环滤泡辅助性T细胞(Tfh)减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is the main cause of late nonrelapse mortality and morbidity after allogeneic stem cell transplantation (allo-SCT). To improve such patients' outcomes, we conducted a phase 2, prospective, multicenter trial to test the efficacy of the addition of rituximab to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly diagnosed cGVHD after allo-SCT. Twenty-four patients (median age, 47 years) with mild (n = 2), moderate (n = 7), or severe (n = 15) cGVHD were included. All patients received rituximab 375 mg/m2 weekly for 4 weeks, followed by a second course 1 month later for patients with partial response. Twenty of 24 patients (83%) were in response at 1 year. Furthermore, among 19 evaluable patients, 14 (74%) were off CSs. The estimated 1-year overall survival was 83%, and the 1-year cumulative incidence of nonrelapse mortality was 14%. One patient died of progressive multifocal leukoencephalopathy. Although PD-L1hi naive B cells were significantly decreased at diagnosis of cGVHD, they increased after anti-CD20 B-cell depletion. In contrast, activated ICOShi PD-1hi circulating T follicular helper (Tfh) cells decreased after rituximab treatment. Overall, the addition of rituximab to corticosteroid and CsA appeared to be safe and effective for first-line treatment of cGVHD. Furthermore, our data suggest that this efficacy may be in part related to an effect on PD-L1hi B cells and Tfh cells. This study was registered at www.clinicaltrials.gov as identifier NCT01135641.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Malard F, Labopin M, Yakoub-Agha I, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017. PMID: 28864814. doi:10.1182/blood-2017-05-786137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。